EBV reactivation following visilizumab.

Three individual patients (open symbols) developed high-level EBV reactivation and died (left panel); overt PTLD was documented in 2 patients (□, ○). The 5 remaining panels (solid symbols) show EBV-DNA copies/mL in individual patients who received preemptive therapy with rituximab (arrows) and did not develop PTLD. The far right panel shows an individual patient who developed asymptomatic PTLD 65 days after visilizumab therapy. The PTLD resolved after 4 additional doses of rituximab and concomitant recovery of T-cell numbers.